Nov 3, 2026Servier's $1.55 billion muscular dystrophy drug fails pivotal trialServier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.Nov 3, 2026·2 sources00
Jun 1, 2026Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 BillionFrench pharmaceutical company Servier will acquire Edgewise Therapeutics' experimental muscular dystrophy drug and related business for up to $2.65 billion. Edgewise will pivot to focus on cardiovascular drugs following the transaction.Jun 1, 2026·2 sources00